<DOC>
	<DOC>NCT01786135</DOC>
	<brief_summary>This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)</brief_summary>
	<brief_title>A Safety Study of SGN-CD19A for B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Pathologically confirmed diagnosis of mantle cell lymphoma, follicular lymphoma Grade 3, diffuse large Bcell lymphoma (DLBCL), including transformed follicular histology, Burkitt lymphoma, or Blineage lymphoblastic lymphoma Relapsed, refractory, or progressive disease following at least 1 prior systemic therapy. Patients with DLBCL or follicular lymphoma Grade 3 must have also received intensive salvage therapy. Eastern Cooperative Oncology Group status of 0 or 1 Measurable disease Allogeneic stem cell transplant (SCT)</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens, CD19</keyword>
	<keyword>B-Lineage Lymphoblastic Lymphoma</keyword>
	<keyword>Burkitt Lymphoma</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>B-Cell Lymphoma</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Monomethylauristatin F</keyword>
	<keyword>Follicular Lymphoma Grade 3</keyword>
</DOC>